Clinical trials
Recurrent or Metastatic Nasopharyngeal Carcinoma clinical trials
Below are recruiting recurrent or metastatic nasopharyngeal carcinoma clinical trials, each written for real people, not researchers. We’re tracking 2,384 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07018947RecruitingPhase 2
Atezolizumab and bevacizumab before and after surgery for liver cancer
This trial tests whether adding two drugs (atezolizumab and bevacizumab) before and after surgery can lower the chance of liver cancer coming back in people with high-risk HCC. You must be eligible for surgical removal of your tumor.
Badalona, BarcelonaAges 18 years+ - NCT04185974Recruiting
Carbon ion re-irradiation for returning head and neck cancer
This trial tests a type of radiation called carbon-ion re-irradiation for people whose head and neck cancer has come back or grown again after earlier radiation. It may help control the cancer after certain surgeries, but it also requires specific safety conditions about timing, prior treatment areas, and overall health.
HeidelbergAges 18 years+ - NCT07071090RecruitingPhase 1
Study of DC50292A for advanced solid tumors with MTAP deletion
This trial tests a new tablet, DC50292A, for people whose cancer has an MTAP gene deletion. It is for patients whose cancer has spread or returned and who have not had success with other treatments.
Fuzhou, FujianAges 18 years+ - NCT07385521Recruiting
AI to predict cancer return after liver surgery
This trial uses artificial intelligence to predict whether colorectal cancer that spread to the liver will come back after surgery. It may help doctors better understand your risk and plan follow-up care.
MilanAges 18 years+ - NCT06930157RecruitingPhase 4
Shenling Baishu Granule to prevent low-risk colon polyp return
This study tests if a Chinese herbal medicine (Shenling Baishu Granule) can help prevent low-risk colon polyps from coming back after they've been removed. It is for people who have had a good colonoscopy and had their polyps taken out within the last 3 months.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05668650RecruitingPhase 3
Study MB12 versus Keytruda for newly diagnosed stage IV lung cancer
This Phase 3 trial compares MB12 with Keytruda (both cancer medicines) for people with newly diagnosed stage IV non-squamous non-small-cell lung cancer. It looks at whether MB12 can work as well or better than Keytruda, and compares safety and immune responses.
Viedma, Río Negro ProvinceAges 18 years+ - NCT07363252Recruiting
Study of why lung cancer returns after osimertinib treatment
This study looks at why lung cancer returns in people who took the targeted pill osimertinib after surgery. If your cancer has come back, researchers will test your tumor or blood sample to understand how the cancer changed.
Bari, BAAges 18 years+ - NCT07359404Enrolling by invitationPhase 2
Sacituzumab Govitecan plus Bevacizumab for metastatic TNBC
This trial tests a combination of two drugs, Sacituzumab Govitecan and Bevacizumab, for people with advanced triple-negative breast cancer that has already been treated. The goal is to see if the combination works better than standard treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT03649048Recruiting
Weekly low-dose or high-dose cisplatin with radiation for head and neck cancer
This trial compares two cisplatin dosing schedules (weekly low-dose vs higher dose less often) given alongside radiation for certain head and neck cancers. It’s testing which schedule works well while keeping side effects manageable during planned, curative-intent radiation.
Hamilton, OntarioAges 18 years+ - NCT06609928RecruitingPhase 1
CAR T cell therapy for children with relapsed AML that has FOLR1
This trial tests a special immune cell treatment (CAR T cells) that target a protein called FOLR1 found on some AML cells. It is for children aged 6 or younger whose leukemia has come back or not responded to treatment.
Seattle, WashingtonAges Up to 6 years - NCT06883747RecruitingEarly Phase 1
Study of BMS-986504 for recurrent brain tumor
This trial tests an experimental drug, BMS-986504, for people with recurrent glioblastoma (a type of brain cancer). The drug targets a specific genetic change in the tumor. It aims to see if the drug can help shrink or slow the tumor.
Phoenix, ArizonaAges 18 years+ - NCT06903117RecruitingPhase 1
CAR T-Cell Therapy for CEA-Positive Advanced Lung Cancer
This early-stage trial tests a special immune cell treatment (CAR T cells) designed to target and attack lung cancer cells that have a protein called CEA on their surface. It's for people with advanced lung cancer who have already tried at least two standard treatments without success.
ShanghaiAges 18 years+ - NCT07165886RecruitingPhase 2/Phase 3
Study of sirolimus and octreotide for advanced neuroendocrine tumors
This trial tests a combination of two drugs, sirolimus and octreotide, for people with advanced neuroendocrine tumors in the digestive system that cannot be removed by surgery and are not making excess hormones. The goal is to see if this combination can help control the tumors.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05730608Recruiting
PET/CT scan test for high-risk breast cancer
This trial studies how an FDG PET/CT scan (a special imaging test that looks for active cancer activity) can be used in people with high-risk primary or recurring breast cancer. It may help doctors better identify areas of concern and guide future care.
DrammenAges 18 years+ - NCT05982678RecruitingPhase 2
Study of a drug for breast cancer that has spread to a few spots
This trial tests a drug for people with HER2-positive breast cancer that has spread to only a few places in the body (up to 5 spots). It aims to see if the treatment works well before starting stronger therapies.
AmsterdamAges 18 years+ - NCT07273708Recruiting
Immune cell study in liver cancer patients on immunotherapy
This study looks at how your immune cells respond to two specific immunotherapy-based treatments for advanced liver cancer. Researchers want to understand why some patients respond well and others do not, which could help improve future care.
Pavia, LombardyAges 18–90 - NCT06570447RecruitingPhase 2
Glofitamab and chidamide for relapsed or refractory DLBCL
This trial tests a combination of two drugs, glofitamab and chidamide, for people with diffuse large B-cell lymphoma (DLBCL) that has come back or not responded after at least two prior treatments. The goal is to see if this combination can help when other options have stopped working.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06894576Recruiting
Creating a risk score for blood clot recurrence and bleeding in cancer patients
This study is for people with cancer who have had a serious blood clot. Researchers want to create a risk score that predicts who might have another clot or a bleeding problem from treatment, so they can better tailor care.
Ottawa, OntarioAges 18 years+ - NCT06843434RecruitingPhase 2
Study of two immunotherapy drugs for rectal cancer
This trial tests a combination of two immunotherapy drugs, botensilimab and balstilimab, for people with newly diagnosed rectal adenocarcinoma that has not spread. The goal is to see if this treatment can shrink the tumor before surgery.
Basking Ridge, New JerseyAges 18 years+ - NCT06531278RecruitingPhase 2
Adebelimab plus chemo for first-line pancreatic cancer with liver spread
This trial tests a combination of immunotherapy (adebelimab) and chemotherapy drugs (irinotecan liposome, oxaliplatin, fluorouracil, and calcium folinate) as a first treatment for pancreatic cancer that has spread to the liver. The goal is to see if this combination is safe and effective.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06936488Enrolling by invitation
Study of Ivonescimab with TAS-102 for advanced colorectal cancer
This trial tests a combination of two drugs – ivonescimab (a type of immunotherapy) and TAS-102 (a chemotherapy) – for people with advanced colorectal cancer that has not responded to at least two prior chemotherapies. The goal is to see if this new combo can shrink tumors or slow cancer growth.
Huai'an, JiangsuAges 18–75 - NCT06541639RecruitingPhase 1
Immune cell therapy for advanced solid tumors
This study tests a new immune cell therapy (EVM16) given alone or with another drug (tislelizumab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination can help shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07252479RecruitingPhase 1
Testing a new RAS inhibitor for advanced solid tumors
This trial is testing a new oral medication (AN9025) for people with advanced solid tumors that have a RAS mutation, such as pancreatic, colorectal, lung, or melanoma. It aims to see if the drug can shrink tumors or slow their growth when other treatments have stopped working.
Orlando, FloridaAges 18 years+ - NCT07123103RecruitingPhase 1
Study of XB371 for advanced solid tumors
This trial tests a new drug called XB371 for people with advanced solid tumors that have come back or spread. It aims to see if the drug is safe and works against the cancer.
Rogers, ArkansasAges 18 years+
Hear when a new Recurrent or Metastatic Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent or metastatic nasopharyngeal carcinoma?
- Yes. Clin2 currently lists 2,384 recruiting recurrent or metastatic nasopharyngeal carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent or metastatic nasopharyngeal carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent or metastatic nasopharyngeal carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Recurrent Nasopharyngeal Carcinoma
- Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- Metastatic Nasopharyngeal Carcinoma
- Metastatic Nasopharyngeal Squamous Cell Carcinoma
- Recurrent Nasopharyngeal Squamous Cell Carcinoma
- Nasopharyngeal Carcinoma
- Metastatic Renal Cell Carcinoma
- Nasopharyngeal Carcinoma (NPC)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.